Cosentyx 125 mg/5 mL (25 mg/mL) injection for intravenous use Images
Generic Name: secukinumab
This medication has been identified as Cosentyx 125 mg/5 mL (25 mg/mL) injection for intravenous use. It is supplied by Novartis Pharmaceuticals Corporation.
Cosentyx is used in the treatment of Hidradenitis Suppurativa; Ankylosing Spondylitis; Enthesitis-Related Arthritis; Non-Radiographic Axial Spondyloarthritis; Plaque Psoriasis and belongs to the drug class interleukin inhibitors. There is no proven risk in humans during pregnancy. Cosentyx 125 mg/5 mL (25 mg/mL) injection for intravenous use is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Cosentyx
- Generic Name
- secukinumab
- Strength
- 125 mg/5 mL (25 mg/mL) injection for intravenous use
- Availability
- Prescription only
- Drug Class
- Interleukin inhibitors
- Pregnancy Category
- B - No proven risk in humans
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Novartis Pharmaceuticals Corporation
- National Drug Code (NDC)
- 00078-1168
More about Cosentyx (secukinumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (245)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.